# To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)

> **NCT06698484** · PHASE2 · RECRUITING · sponsor: **National University of Malaysia** · enrollment: 20 (estimated)

## Conditions studied

- Relapsed/Refractory B- Cell Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** CAR-T cells

## Key facts

- **NCT ID:** NCT06698484
- **Lead sponsor:** National University of Malaysia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-06-03
- **Primary completion:** 2025-06-02
- **Final completion:** 2026-06-02
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06698484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06698484, "To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06698484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*